Artiva Biotherapeutics vs BioRestorative Therapies
ARTV and BRTX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARTV and BRTX compare
Artiva Biotherapeutics is the larger company, worth 5.2 times as much as BioRestorative Therapies ($196M against $38.0M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARTV | BRTX |
|---|---|---|
| Size and price | ||
| Market cap | $196M | $38.0M |
| Share price | $4.01 | $1.49 |
| Change, 1 year | 0.75% | −94.6% |
| Change, 5 years | – | −98.9% |
| Beta (5Y) | 2.30 | 1.07 |
| Employees | 104 | 14 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 106× |
| P/B | 0.6× (better) | 12.5× |
| FCF yield | −44.2% | – |
| Growth | ||
| Revenue growth (TTM) | – | −8.5% |
| Revenue growth, 5Y average | – | 36.1% |
| Profitability | ||
| Gross margin | – | 92.1% |
| Operating margin | – | −3975% |
| Net margin | – | −3090% |
| Return on equity | −43.6% (better) | −241% |
| Return on invested capital | −2120% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 19.88 (better) | 2.35 |
| Altman Z-score | 3.69 (better) | −47.28 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 83.2% | 0.52% |
| Held by insiders | 68.3% | 9.6% |
| Insider net buying, 12 months | $106M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 19.0% | 0.16% |
Go deeper
- ARTV stock overview
- ARTV income statement
- ARTV valuation and score
- BRTX stock overview
- BRTX income statement
- BRTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.